Specifically, increased expression of KCNJ11 (the targetgene of sulfonylureas) and SLC5A2 (the target gene of SGLT2 inhibitors)was associated with a heightened risk of ischemic stroke. This evidence concerns the gene SLC5A2 and ischemic stroke.